We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

146 hedge funds and large institutions have $515M invested in Eagle Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 53

1% more capital invested

Capital invested by funds: $508M → $515M (+$7.6M)

6% less funds holding

Funds holding: 155 → 146 (-9)

43% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 21

Holders
146
Holders Change
-9
Holders Change %
-5.81%
% of All Funds
2.54%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
55
Reduced
53
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$11.4M
2
BIP
Brandes Investment Partners
California
+$9.38M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$5.86M
4
Wells Fargo
Wells Fargo
California
+$4.97M
5
BlackRock
BlackRock
New York
+$4.16M

Top Sellers

Rank Fund Capital Flow
1
PWAM
Park West Asset Management
California
-$18.8M
2
AC
Armistice Capital
New York
-$8.01M
3
Two Sigma Investments
Two Sigma Investments
New York
-$5.31M
4
Norges Bank
Norges Bank
Norway
-$3.55M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$3.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$4.93M -$205K -4,964 -4%
Principal Financial Group
27
Principal Financial Group
Iowa
$4.32M -$398K -9,653 -9%
KCM
28
Kennedy Capital Management
Missouri
$4.31M -$515K -12,476 -11%
TLP
29
Tri Locum Partners
New York
$4.06M +$3.92M +94,922 New
Charles Schwab
30
Charles Schwab
California
$3.45M +$151K +3,653 +5%
KAM
31
Krensavage Asset Management
New York
$3.03M +$2.92M +70,804 New
Millennium Management
32
Millennium Management
New York
$2.86M -$809K -19,598 -23%
FP
33
Foundry Partners
Minnesota
$2.85M -$503K -12,186 -15%
Bank of America
34
Bank of America
North Carolina
$2.59M -$209K -5,069 -8%
AQR Capital Management
35
AQR Capital Management
Connecticut
$2.38M -$235K -5,702 -9%
SDIC
36
South Dakota Investment Council
South Dakota
$2.38M +$2.29M +55,594 New
William Blair & Company
37
William Blair & Company
Illinois
$2.31M -$213K -5,150 -9%
Citadel Advisors
38
Citadel Advisors
Florida
$2.12M -$1.65M -40,061 -45%
PPA
39
Parametric Portfolio Associates
Washington
$2.1M +$386K +9,347 +23%
N
40
Nuveen
North Carolina
$2.08M -$172K -4,159 -8%
SG Americas Securities
41
SG Americas Securities
New York
$2.02M -$368K -8,906 -16%
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$1.83M +$1.03M +25,050 +142%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$1.82M -$2.25M -54,620 -56%
Citigroup
44
Citigroup
New York
$1.81M -$13.9K -337 -0.8%
GC
45
Globeflex Capital
California
$1.81M +$334K +8,094 +24%
AllianceBernstein
46
AllianceBernstein
Tennessee
$1.81M +$295K +7,157 +20%
SGI
47
Summit Global Investments
Utah
$1.64M -$6.03K -146 -0.4%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.6M +$38.5K +933 +3%
HPCM
49
Hein Park Capital Management
New York
$1.37M +$1.32M +31,977 New
Two Sigma Advisers
50
Two Sigma Advisers
New York
$1.16M -$3.49M -84,600 -76%
1
2
3 4 5

EGRX Hedge Fund Activity: Q2 2021 in Review

146 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2021, worth a combined $515M — up 1.5% from $508M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of EGRX and 12 opened new positions — a net loss of 9 holders — while 53 trimmed existing stakes and 55 added.

The largest buyer was JP Morgan Chase, adding an estimated $11.4M. The largest seller was Park West Asset Management, exiting entirely with an estimated $18.8M sold.

  • 146 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2021, down from 155 in Q1 2021.
  • Funds reported $515M of Eagle Pharmaceuticals, Inc. stock for Q2 2021, up 1.5% quarter-over-quarter.
  • 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2021 and 21 closed out, a net change of -9 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2021 was JP Morgan Chase, an estimated $11.4M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q2 2021 was Park West Asset Management, an estimated $18.8M sold.

Based on aggregated 13F filings for Q2 2021.